{"name":"Roxall Medicina España S.A","slug":"roxall-medicina-espa-a-s-a","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Allergovac depot","genericName":"Allergovac depot","slug":"allergovac-depot","indication":"Other","status":"phase_2"},{"name":"Allergovac himenoptera","genericName":"Allergovac himenoptera","slug":"allergovac-himenoptera","indication":"Other","status":"phase_2"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Allergovac Poliplus","genericName":"Allergovac Poliplus","slug":"allergovac-poliplus","indication":"Allergic rhinitis and/or allergic asthma caused by multiple allergens","status":"phase_2"}]}],"pipeline":[{"name":"Allergovac Poliplus","genericName":"Allergovac Poliplus","slug":"allergovac-poliplus","phase":"phase_2","mechanism":"Allergovac Poliplus is an allergen immunotherapy vaccine designed to desensitize the immune system to multiple allergens through controlled exposure.","indications":["Allergic rhinitis and/or allergic asthma caused by multiple allergens"],"catalyst":""},{"name":"Allergovac depot","genericName":"Allergovac depot","slug":"allergovac-depot","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Allergovac himenoptera","genericName":"Allergovac himenoptera","slug":"allergovac-himenoptera","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipwJBVV95cUxOOFVzZGhrVzRxTDVGcDJsZlVhWkRYRlc5czJ3LWd4bV9jdVpkaGxaRmdrU0FYX0tEQm1ROFNIQ3RDLUlqd1I0N0RhSGhLSk1sQjFRTDMyR2Q1bmVTM2lEVWthSnF3OWU2MkZiYlF3cXFUd0ZDSXA4dHlxOC1VaEp4Y2lBak5acXhjUWp6R1RYbkl5b0NOWXNFRGRsZC1nTGVMYUFfXzhNbW5WVEJwY2s0bmNIVVE0cmVWUmQzNTN2VmxfbnkzS1dHaGdJLXRlODBwcWRMYWYzd0R1OGdLRkRWU0ZjNEZpRG1ONF96X2wyb0t2dGFHMXRxUEFFdmc4cGU1eGZXcDNlUk9KbE9raTZvSUVUdUhDM2FZR1VNUWNGWW1HMXNGTmdr?oc=5","date":"2025-10-13","type":"pipeline","source":"PR Newswire","summary":"Allergic Rhino-Conjunctivitis Market Poised for Significant Growth in the Coming 10 Years Amid Increasing Therapeutic Advancements | DelveInsight - PR Newswire","headline":"Allergic Rhino-Conjunctivitis Market Poised for Significant Growth in the Coming 10 Years Amid Increasing Therapeutic Ad","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_2":3},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}